| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief Reviews |
From the Vascular Biology Unit (J.G., J.M.), School of Medicine, James Cook University, Townsville, Australia; Cardiovascular Research Center (A.D.), Gill Heart Institute, University of Kentucky, Lexington; and the School of Surgery and Pathology (P.N.), University of Western Australia, Fremantle Hospital, Fremantle, Western Australia.
Correspondence to Professor Jonathan Golledge, Director, The Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland 4811, Australia. E-mail Jonathan.Golledge{at}jcu.edu.au
Series Editor: Robert W. Thompson
Abdominal Aortic Aneurysms: Pathophysiological Mechanisms and Clinical Implications
ATVB In Focus
Previous Brief Reviews in this Series:
Powell JT, Brady AR. Detection, management, and prospects for the medical treatment of small abdominal aortic aneurysms. 2004;24:241245.
Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. 2004;24:429434.
Pasterkamp G, Galis ZS, de Kleijn DPV. Expansive arterial remodeling: location, location, location. 2004;24:650657.
Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. 2006;26:987994.
Abdominal aortic aneurysm (AAA) affects approximately 5% of elderly men and is responsible for a significant number of deaths in Western Countries. At present surgery by open or endovascular means is the only widely used therapy for this condition. In this review we examine the risk factors, serum, and genetic associations of AAA. Epidemiology studies suggest that smoking cessation and control of cholesterol and blood pressure should reduce the number of patients developing AAA. Natural history studies suggest that smoking cessation should reduce the rate of progression of AAA. Clear level 1 evidence for drug treatments of AAA are presently lacking; however, animal and human in vitro studies suggest that medication targeted at reducing inflammation and proteolysis are most likely to be beneficial, with limited data to support the use of statins, Angiotensin II inhibitors, and macrolides. Work has commenced in understanding which patients, identified by clinical, serum, and genotype, are more at risk of AAA progression and thus should be selected out for aggressive treatment. Well designed large multicenter randomized controlled trials are required to examine the medical treatment of AAA.
Abdominal aortic aneurysm is associated with significant morbidity and mortality. Presently medical therapy for this condition has been neglected. This article summarises efforts to better understand the pathology of AAA to develop such treatments.
Key Words: abdominal aortic aneurysm pathogenesis medication
This article has been cited by other articles:
![]() |
S. H. Forsdahl, S. Solberg, K. Singh, and B. K Jacobsen Abdominal aortic aneurysms, or a relatively large diameter of non-aneurysmal aortas, increase total and cardiovascular mortality: the Tromso study Int. J. Epidemiol., November 12, 2009; (2009) dyp320v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Arapoglou, A. Kondi-Pafiti, D. Rizos, T. Kotsis, C. Kalkandis, and K. Katsenis The Influence of Total Plasma Homocysteine and Traditional Atherosclerotic Risk Factors on Degree of Abdominal Aortic Aneurysm Tissue Inflammation Vascular and Endovascular Surgery, October 1, 2009; 43(5): 473 - 479. [Abstract] [PDF] |
||||
![]() |
J. H.F. Rudd, M. Elkhawad, and Z. A. Fayad Vascular Imaging with 18F-FDG PET/CT: Optimal 18F-FDG Circulation Time? J. Nucl. Med., September 1, 2009; 50(9): 1560 - 1560. [Full Text] [PDF] |
||||
![]() |
L.-N. Zhang, J. Vincelette, Y. Cheng, U. Mehra, D. Chen, S.-K. Anandan, R. Gless, H. K. Webb, and Y.-X. Wang Inhibition of Soluble Epoxide Hydrolase Attenuated Atherosclerosis, Abdominal Aortic Aneurysm Formation, and Dyslipidemia Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1265 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Aoki, H. Kataoka, R. Ishibashi, K. Nozaki, K. Egashira, and N. Hashimoto Impact of Monocyte Chemoattractant Protein-1 Deficiency on Cerebral Aneurysm Formation Stroke, March 1, 2009; 40(3): 942 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Golledge, P. S. Tsao, R. L. Dalman, and P. E. Norman Circulating Markers of Abdominal Aortic Aneurysm Presence and Progression Circulation, December 2, 2008; 118(23): 2382 - 2392. [Full Text] [PDF] |
||||
![]() |
K. I. Paraskevas, C. D. Liapis, G. Hamilton, and D. P. Mikhailidis Are Statins an Option in the Management of Abdominal Aortic Aneurysms? Vascular and Endovascular Surgery, May 1, 2008; 42(2): 128 - 134. [Abstract] [PDF] |
||||
![]() |
M. Wang, E. Lee, W. Song, E. Ricciotti, D. J. Rader, J. A. Lawson, E. Pure, and G. A. FitzGerald Microsomal Prostaglandin E Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin II-Induced Abdominal Aortic Aneurysm Formation Circulation, March 11, 2008; 117(10): 1302 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Golledge, M. Karan, C. S. Moran, J. Muller, P. Clancy, A. E. Dear, and P. E. Norman Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions Eur. Heart J., March 1, 2008; 29(5): 665 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kuivaniemi, C. D. Platsoucas, and M. D. Tilson III Aortic Aneurysms: An Immune Disease With a Strong Genetic Component Circulation, January 15, 2008; 117(2): 242 - 252. [Full Text] [PDF] |
||||
![]() |
J. Golledge, P. Clancy, K. Jamrozik, and P. E. Norman Obesity, Adipokines, and Abdominal Aortic Aneurysm: Health in Men Study Circulation, November 13, 2007; 116(20): 2275 - 2279. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Daugherty and L. A. Cassis Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin converting enzyme inhibitors and aortic rupture: population based case control study. Lancet. 2006;368:659-665 Perspectives in Vascular Surgery and Endovascular Therapy, September 1, 2007; 19(3): 342 - 344. [Abstract] [PDF] |
||||
![]() |
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |